Poolbeg Pharma's Jeremy Skillington talks to Proactive London after signing a deal with CytoReason, a leading artificial intelligence (AI) to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples.
The company develops computational disease models for efficient drug discovery and development.
The partnership aims to harness the insights of Poolbeg’s unique repository of influenza human challenge trial data together with CytoReason’s leading and validated AI technology.